Sentences with phrase «islet cell replacement therapy»
The company is the first to advance an encapsulated islet cell replacement therapy for type -LSB-...]
http://viacyte.com/
Diabetes Forecast highlighted ViaCyte's first - of - a-kind islet cell replacement therapy in an article discussing twelve innovative products being developed to treat and manage type 1 diabetes.
San Diego, August 1, 2017 — ViaCyte, Inc., a privately - held, leading regenerative medicine company, announced today that the first patients have been implanted with the PEC - Direct ™ product candidate, a novel islet cell replacement therapy in development as a functional cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.
«The PEC - Direct islet cell replacement therapy is designed to help patients with the most urgent medical need.»
The Company's pluripotent stem cell - derived islet cell replacement therapy, the PEC - Direct ™ product candidate, has the potential to be a breakthrough treatment for high - risk type 1 diabetes.
«JDRF remains dedicated to accelerating the delivery of beta cell replacement therapies to the T1D community, and we commend ViaCyte in its announcement of the first patients to be implanted with the PEC - Direct islet cell replacement therapy,» said Derek Rapp, JDRF President and Chief Executive Officer.
The company is the first to advance an encapsulated islet cell replacement therapy for type 1 diabetes into clinical trials.
ViaCyte's PEC - EncapTM (also known as VC - 01TM) product candidate is the first pluripotent stem cell - derived islet cell replacement therapy for the treatment of type 1 diabetes in clinical - stage development.
ViaCyte has two stem cell - based islet cell replacement therapies in clinical development.
Not exact matches
Diabetes researchers are considering various replacements for insulin injections: Transplanting new pancreatic islet cells that make insulin, coaxing the patient's own islets to regenerate, or treating diabetics early in the disease with immune - suppressing therapies to prevent their body from destroying the rest of their pancreatic islets.
«The loss of insulin - producing beta cells leads to type 1 diabetes, making it an ideal target for cell replacement therapy,» said James Shapiro, MD, PhD, FRCSC, Director of the Clinical Islet Transplant Program, University of Alberta.
«ViaCyte was the first to differentiate human stem cells into glucose - responsive, insulin - producing cells, and now we are running the first and only clinical trials of stem cell - derived islet replacement therapies for type 1 diabetes,» said Paul Laikind, PhD, President and CEO of ViaCyte.
In addition, ViaCyte launched the first clinical trials for stem cell - derived islet replacement therapies for type 1 diabetes.
SAN DIEGO and BETHESDA, MD, March 3, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Eugene Brandon, Director of Strategic Relations and Project Management, at the JDRF TypeOneNation Summit.
SAN DIEGO, April 20, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced four presentations at upcoming healthcare events.
SAN DIEGO, September 9, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced participation on a panel at the 2016 BioPharm ™ America — 9th Annual International Partnering Conference.
SAN DIEGO, March 17, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Paul Laikind, President and CEO, at the third annual Regen Med Investor Day co-hosted by the Alliance for Regenerative Medicine (ARM) and top financial firm Piper Jaffray.
In addition, the funding will be used to support other operations including the continued development of the PEC - Encap ™ product candidate, ViaCyte's stem cell - derived islet replacement therapy that is being developed as a treatment for all diabetes patients who require insulin to control their disease.
San Diego, January 8, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Company's Phase 1/2 clinical trial of its VC - 01TM product candidate.
San Diego, California, October 6, 2014 — ViaCyte, Inc., a privately - held regenerative medicine company developing a stem cell - derived islet replacement therapy for the treatment of diabetes, called VC - 01 ™, will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follcell - derived islet replacement therapy for the treatment of diabetes, called VC - 01 ™, will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follCell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follows:
SAN DIEGO, March 1, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced presentations at the JDRF TypeOneNation Summit meetings being held in Washington DC and Los Angeles.
The PEC - Encap (also known as VC - 01) product candidate is designed to deliver stem cell - derived islet replacement therapies to patients with type 1 diabetes as well as patients with type 2 disease that require insulin.
The VC - 01 product candidate is the first embryonic stem cell - derived islet replacement therapy to reach clinical testing and is currently being evaluated in patients with T1D who have minimal to no insulin - producing beta cell function.
SAN DIEGO, June 22, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced two presentations at ISSCR 2016 Annual Meeting.